Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
adsCLkdH0C3SRFhn
Listen
